Slide 1: Processa Pharmaceuticals 2Q 2021 Earnings Call
G Processa Pharmaceuticals 2Q 2021 Earnings Call | August 12, 2021
Slide 2: Disclaimer: Forward Looking Statements
Disclaimer: Forward Looking Statements The following summary is provided for informational purposes only and does not constitute an offer or solicitation to acquire interests in the investment or any related or associated company. The information contained here is general in nature and is not intend
Slide 3: Processa's Differentiated Approach
Processa’s Differentiated Approach Repeatable, Capital-efficient Blueprint Platform with Potential to Generate Significant ROI e os DEVELOP NOT DISCOVER eo REGULATORY SCIENCE PLATFORM e -—*, — Unmet Medical Need + Efficacy Evidence + Regulatory Science + Capital Efficiency +) CuteIK7 aif iste), © Cl
Slide 4: Processa Pipeline — Multiple Opportunities For Success
Processa Pipeline — Multiple Opportunities For Success Drug Disease Target Preclin | Phase Status Milestones ‘J PCS499 Ulcerative 2 Patients Enrolled; 1 Patient in Interim Analysis 1H’22; Phase 2B Necrobiosis LD ==> Screening; 10 Patients Pre-Screen Final Analysis 2H’22; Lipoidica Failures; 3/9 Site
Slide 5: PCS499 to Be First to Market for the Treatment of Ulcerative NL
PCS499 to Be First to Market for the Treatment of Ulcerative Necrobiosis Lipoidica (UNL) Severe NL > Skin, tissue below the skin becomes necrotic, last from months to years with complications such as infections, amputation; Histopathology # diabetic ulcers > 30% of NL patients have painful ulcers oc
Slide 6: Unmet Medical Need, Evidence of Clinical Efficacy, PCS499 Improves Benefit-Risk
Unmet Medical Need, Evidence of Clinical Efficacy, PCS499 Improves Benefit-Risk Vv Baseline } - PCS499 is the deuterated analog of a major metabolite of PTX; has identical metabolites and pharmacological targets but PK of 499 + metabolites is different than PTX _+ metabolites resulting in a better 4
Slide 7: PCS12852 Potent-Selective 5HT4 Agonist: Gastroparesis ($1 B Market)
PCS12852 Potent-Selective 5HT4 Agonist: Gastroparesis ($1 B Market) Gastric Emptying Rate (%) using 13C-Spirulina Submit IND for Phase 2A Trial in 3Q’21, FPI in 1Q’22 SiS Other 5HT4 Drug Dopamine D2 (e.g., Cisapride, Antagonist Prucalopride, (.e.g,, Mosapride) Metoclopramide) Binding + Very specific
Slide 8: PCS12852 Potent-Selective 5HT4 Agonist for Treatment of Gastroparesis
PCS12852 Potent-Selective 5HT4 Agonist for Treatment of Gastroparesis > Economic Value: Initial Markets * Prevalence of moderate to severe gastroparesis in U.S. reported to be over 200,000 to > 1,500,000 patients depending on formal diagnosis vs symptom presentation « Present use of approved drugs a
Slide 9: In Licensed PCS3117 for Gemcitabine Resistant Pancreatic and Lung Cancer Patients
In Licensed PCS3117 for Gemcitabine Resistant Pancreatic and Lung Cancer Patients > PCS3117 has similar structure to gemcitabine but is activated through a different pathway and causes cancer cell apoptosis in more ways than gemcitabine > PCS3117 has been shown in gemcitabine resistant cancer patien
Slide 10: Target Population: More Likely to Respond to or Activate PCS3117 than Gemcitabine
Target Population: More Likely to Respond to or Activate PCS3117 than Gemcitabine > Biomarker assays are being developed and evaluated to potentially define a targeted, personalized medicine UCK2 Expression dCK Expression approach to identifying patients who will respond to 3117 o | e4 5 better than
Slide 11: PCS6422 Combined with Capecitabine To Provide Better Safety/Efficacy Profile
PCS6422 Combined with Capecitabine To Provide Better Safety/Efficacy Profile PCS6422 Irreversibly Inhibits Dihydropyrimidine Dehydrogenase (DPD) Enzyme Cqpecieltine 6422 Inhibits DPD Allowing Two Ways to Win (Xeloda®) > Lower Side Effects by Lowering 5-FU Metabolite FBAL- Potentially Improve QOL & R
Slide 12: Unmet Medical Need and Evidence of Clinical Benefit
Unmet Medical Need and Evidence of Clinical Benefit 20 > Safety Differentiation of 6422 + Capecitabine vs Existing Chemotherapy Dacranse Incidence of HFS (Grads 3&4) FBAL Side Effects * 50-70% of capecitabine patients have adverse events from FBAL = resulting in decreasing capecitabine dose or stopp
Slide 13: Summary Timeline of Pipeline and Key Clinical Milestones
Summary Timeline of Pipeline and Key Clinical Milestones 1H 1H 2021 2022 PCS499 ¢ Initiate Sites ¢ Interim Analysis ¢ Final Analysis ¢ Phase 3 Trial Phase 2B « FPI + NDA Submission PCS12852 + Pre-IND Meeting +* IND Submission ° FPI * Final Analysis ¢ Final Analysis Phase 2A + Prepare IND (3021) + Ph
Slide 14: What's Expected Over the Next Months?
What’s Expected Over the Next 6 Months? > Complete enrollment of patients for the interim analysis of PCS499 > IND Clearance for PCS12852 in Gastroparesis > Analysis of Cohort 1 & 2 in the 6422 Phase 1B Dose Escalation Study > Development of PCS3117 Biomarker Assays and Initiation of Assay Validatio